Synairgen has raised £80m to fund a Phase III trial for SNG001 in COVID-19 disease, which is due to commence in Q4 2020 and will be run globally by Parexel, with results expected in Q2 2021, and scale up manufacturing. This follows a successful pre-IND meeting with the FDA, which provided the guidance to commence such a study. Assuming that this trial replicates the results seen in the 100-patient Phase II trial, we would expect Emergency Use Approval (EUA) to follow shortly thereafter. Meanwhil ....
16 Oct 2020
Synairgen - £80m funding for COVID-19 study and supply chain
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Synairgen - £80m funding for COVID-19 study and supply chain
Synairgen plc (SNG:LON) | 6.6 0 2.3% | Mkt Cap: 13.3m
- Published:
16 Oct 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
17
Synairgen has raised £80m to fund a Phase III trial for SNG001 in COVID-19 disease, which is due to commence in Q4 2020 and will be run globally by Parexel, with results expected in Q2 2021, and scale up manufacturing. This follows a successful pre-IND meeting with the FDA, which provided the guidance to commence such a study. Assuming that this trial replicates the results seen in the 100-patient Phase II trial, we would expect Emergency Use Approval (EUA) to follow shortly thereafter. Meanwhil ....